Vascular effects of sphingolipids

Acta Paediatrica, International Journal of Paediatrics

Volumn 96, Issue SUPPL. 455, 2007, Pages 44-48

  Michel, Martin C ^a,b   Mulders, Arthur C M ^a   Jongsma, Maikel ^a   Alewijnse, Astrid E ^a   Peters, Stephan L M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Ceramide; Endothelium; Sphingosine 1 phosphate; Sphingosine kinase; Sphingosylphosphorylcholine; Vascular smooth muscle

Indexed keywords

ACETYLCHOLINE; ACYLSPHINGOSINE DEACYLASE; ANGIOTENSIN II; CALCIUM ION; CERAMIDE; HIGH DENSITY LIPOPROTEIN; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN KINASE B; PROTEIN KINASE C; RECEPTOR SUBTYPE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE; VASOACTIVE AGENT;

BLOOD VESSEL FUNCTION; BLOOD VESSEL TONE; CONFERENCE PAPER; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; VASOCONSTRICTION; VASODILATATION;

HUMANS; LYSOPHOSPHOLIPIDS; PHOSPHORYLCHOLINE; SPHINGOLIPIDS; SPHINGOSINE; VASOCONSTRICTION; VASODILATION;

EID: 33947594303     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2007.00207.x     Document Type: Conference Paper

References (62)

1. Yatomi Y, Ozaki Y, Ohmori T, Igarashi Y. Sphingosine 1-phosphate: synthesis and release. Prostaglandins Other Lipid Mediat 2001; 64: 107-22.
2. Alewijnse AE, Peters SL, Michel MC. Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br J Pharmacol 2004; 143: 666-84.
3. Bitar KN, Yamada H. Modulation of smooth muscle contraction by sphingosylphosphorylcholine. Am J Physiol 1995; 269: G370-7.
4. Johns DG, Osborn H, Webb RC. Ceramide: a novel cell signaling mechanism for vasodilation. Biochem Biophys Res Commun 1997; 237: 95-7.
5. Bischoff A, Czyborra P, Fetscher C, Meyer Zu Heringdorf D, Jakobs KH, et al. Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. Br J Pharmacol 2000; 130: 1871-7.
6. Bischoff A, Czyborra P, Meyer Zu Heringdorf D, Jakobs KH, Michel MC. Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br J Pharmacol 2000; 130: 1878-83.
7. Watterson KR, Ratz PH, Spiegel S. The role of sphingosine-1-phosphate in smooth muscle contraction. Cell Signal 2005; 17: 289-98.
8. Hemmings DG. Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine. Naunyn- Schmiedeberg's Arch Pharmacol 2006; 373: 18-29.
9. 3. Circ Res 2005; 96: 913-20.
10. Bischoff A, Finger J, Michel MC. Nifedipine inhibits sphinogosine-1- phosphate-induced renovascular contraction in vitro and in vivo. Naunyn- Schmiedeberg's Arch Pharmacol 2001; 364: 179-82.
11. Tosaka M, Okajima F, Hashiba Y, Saito N, Nagano T, Watanabe T, et al. Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke 2001; 32: 2913-9.
12. Czyborra C, Bischoff A, Michel MC. Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine. Naunyn- Schmiedeberg's Arch Pharmacol 2006; 373: 37-44.
13. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004; 309: 758-68.
14. Sugiyama A, Aye NN, Yatomi Y, Ozaki Y, Hashimoto K. Effects of sphingosine 1-phosphate, a naturally occurring biologically active lysophospholipid, on the rat cardiovascular system. Jpn J Pharmacol 2000; 82: 338-42.
15. 3. J Clin Invest 2004; 113: 569-81.
16. Czyborra P, Saxe M, Fetscher C, Meyer Zu Heringdorf D, Herzig S, Jakobs KH, et al. Transient relaxation of rat mesenteric microvessels by ceramides. Br J Pharmacol 2002; 135: 417-26.
17. Hedemann J, Fetscher C, Michel MC. Comparison of noradrenaline and lysosphingolipid-induced vasoconstriction in mouse and rat small mesenteric arteries. Auton Autacoid Pharmacol 2004; 24: 77-85.
18. 2+-sensitization of mesenteric artery contraction in spontaneously hypertensive rat. Naunyn- Schmiedeberg's Arch Pharmacol 2006; 373: 30-6.
19. Johns DG, Jin JS, Webb RC. The role of the endothelium in ceramide-induced vasodilation. Eur J Pharmacol 1998; 349: R9-10.
20. i in rat aortic smooth muscle. Lipids 1999; 34: 689-95.
21. 2+ concentration. Naunyn- Schmiedeberg's Arch Pharmacol 2005; 372: 242-50.
22. Roviezzo F, Bucci M, Delisle C, Brancaleone V, Di Lorenzo A, Mayo IP, et al. Essential requirement for sphingosine kinase activity in eNOS-dependent NO release and vasorelaxation. Faseb J 2006; 20: 340-2.
23. Levade T, Augé N, Veldman RJ, Cuvillier O, Nègre-Salvayre A, Salvayre R. Sphingolipid mediators in cardiovascular cell biology and pathology. Circ Res 2001; 89: 957-68.
24. Sugiyama A, Yatomi Y, Ozaki Y, Hashimoto K. Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res 2000; 46: 119-25.
25. Coussin F, Scott RH, Wise A, Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res 2002; 91: 151-7.
26. 2. Cardiovasc Res 2003; 58: 170-7.
27. 3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol 2003; 469: 125-34.
28. Dantas AP, Igarashi J, Michel T. Sphingosine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol 2003; 284: H2045-52.
29. 2+ elevation in endothelial cells in situ and causes endothelium-dependent relaxation through nitric oxide production in bovine coronary artery. FEBS Lett 1999; 457: 375-80.
30. Hemmings DG, Xu Y, Davidge ST. Sphingosine 1-phosphate-induced vasoconstriction is elevated in mesenteric resistance arteries from aged female rats. Br J Pharmacol 2004; 143: 276-84.
31. Ca channel activity and vascular tone in coronary arteries. Hypertension 1999; 33: 1441-6.
32. i in canine cerebral vascular muscle. Am J Physiol Heart Circ Physiol 2000; 278: H1421-8.
33. Altura BM, Gebrewold A, Zheng T, Altura BT. Sphingomyelinase and ceramide analogs induce vasoconstriction and leukocyte-endothelial interactions in cerebral venules in the intact rat brain: Insight into mechanisms and possible relation to brain injury and stroke. Brain Res Bull 2002; 58: 271-8.
34. Zhang DX, Zou AP, Li PL. Ceramide reduces endothelium-dependent vasodilation by increasing superoxide production in small bovine coronary arteries. Circ Res 2001; 88: 824-31.
35. Bornfeldt KE, Graves LM, Raines EW, Igarashi Y, Wayman G, Yamamura S, et al. Sphingosine-1-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: spatial and temporal modulation of PDGF chemotactic signal transduction. J Cell Biol 1995; 130: 193-206.
36. + channels. Biochem Pharmacol 2003; 66: 1861-70.
37. 2+ in vascular smooth muscle: effects on CREB activation. Br J Pharmacol 2006; 147: 351-9.
38. 2+-dependent pathway. Am J Physiol 1998; 275: C1255-63.
39. 2+ signalling mechanisms induced by ATP and sphingosylphosphorylcholine in porcine aortic smooth muscle cells. Br J Pharmacol 2000; 129: 1365-74.
40. 2+-sensitization of vascular smooth muscle contraction: possible involvement of rho-kinase. FEBS Lett 2000; 482: 85-90.
41. Igarashi J, Michel T. Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase beta. Evidence for divergence and convergence of receptor-regulated endothelial nitric-oxide synthase signaling pathways. J Biol Chem 2001; 276: 36281-8.
42. Scherer EQ, Lidington D, Oestreicher E, Arnold W, Pohl U, Bolz SS. Sphingosine-1-phosphate modulates spiral modiolar artery tone: a potential role in vascular-based inner ear pathologies? Cardiovasc Res 2006; 70: 79-87.
43. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, Calmels T. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 2002; 50: 661-70.
44. 1 receptor in adult tissues. Prostaglandins Other Lipid Mediat 2004; 73: 141-50.
45. Tamama K, Kon J, Sato K, Tomura H, Kuwabara A, Kimura T, et al. Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells. Biochem J 2001; 353: 139-46.
46. Ryu Y, Takuwa N, Sugimoto N, Sakurada S, Usui S, Okamoto H, et al. Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells. Circ Res 2002; 90: 325-32.
47. Yamaguchi H, Kitayama J, Takuwa N, Arikawa K, Inoki I, Takehara K, et al. Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. Biochem J 2003; 374: 715-22.
48. 2 pathway in human coronary artery smooth muscle cells. Mol Pharmacol 2005; 67: 1177-85.
49. i-coupled cell surface receptor. Potential involvement in angiogenesis. J Biol Chem 1999; 274: 35343-50.
50. Kimura T, Watanabe T, Sato K, Kon J, Tomura H, Tamama K, et al. Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem J 2000; 348: 71-6.
51. Hla T, Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem 1990; 265: 9308-13.
52. Lee M-J, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99: 301-12.
53. 1 influences multiple functions of human endothelial cells. Arterioscler Thromb Vasc Biol 2005; 25: 546-52.
54. Uhlenbrock K, Huber J, Ardati A, Busch AE, Kostenis E. Fluid shear stress differentially regulates gpr3, gpr6, and gpr12 expression in human umbilical vein endothelial cells. Cell Physiol Biochem 2003; 13: 75-84.
55. Alewijnse AE, Michel MC. Sphingosine-1-phosphate and sphingosylphosphorylcholine: two of a kind? Br J Pharmacol 2006; 147: 347-8.
56. 3H]-dihydrosphingosine-1-phosphate. Br J Pharmacol 2004; 142: 851-60.
57. Hla T. Sphingosine 1-phosphate receptors. Prostaglandins Other Lipid Mediat 2001; 64: 135-42.
58. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, Yasue H. Effects of sphingomyelinase and sphingosine on arterial vasomotor regulation. J Lipid Res 1996; 37: 1601-8.
59. 2+ mobilization in rat aortic smooth muscle. Eur J Pharmacol 2000; 391: 127-35.
60. Bolz SS, Vogel L, Sollinger D, Derwand R, Boer C, Pitson SM, et al. Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase. Circulation 2003; 108: 342-7.
61. 2+ signalling by G-protein-coupled receptors. EMBO J 1998; 17: 2830-7.
62. Mulders AC, Hendriks-Balk MC, Mathy MJ, Michel MC, Alewijnse AE, Peters SL. Sphingosine kinase-dependent activation of endothelial nitric oxide synthase by angiotensin II. Arterioscler Thromb Vasc Biol 2006; 26: 2043-8.